Navigation Links
Reinventing technology assessment for the 21st century
Date:4/27/2010

blic engagement.

"In the 15 years since OTA was closed, TA has progressed significantly in Europe. It is time for the U.S. to institutionalize a serious, continuous and nonpartisan capability to assess the broad social, ethical, legal, and economic impacts of emerging science and technology in areas such as nanotechnology, biotechnology, and earth systems engineering," said David Rejeski, who directs the Wilson Center program.

In the report, Dr. Sclove recommends creating a nationwide Expert & Citizen Assessment of Science & Technology (ECAST) network that will combine the skills of nonpartisan policy research organizations with the research strengths of universities and the public outreach and education capabilities of science museums. Founding partners in ECAST include the Science and Technology Innovation Program at the Wilson Center,, the Boston Museum of Science, Arizona State University, ScienceCheerleader, and the Loka Institute.


'/>"/>

Contact: Patrick Polischuk
patrick.polischuk@wilsoncenter.org
202-691-4283
Project on Emerging Nanotechnologies
Source:Eurekalert

Page: 1 2

Related biology news :

1. Advance made in thin-film solar cell technology
2. Bionanotechnology has new face, world-class future at Florida State
3. DOD funds tiny cave camera and iris recognition technology for military, homeland security
4. Genetically engineered crops benefit many farmers, but the technology needs proper management to remain effective
5. New patented technology for improving cardiac CTs receives NIH support
6. Doubled haploid technology for quickly developing inbred corn lines offered at ISU
7. New technology enables machines to detect microscopic pathogens in water
8. Biogas technology with potential to save thousands of lives to be featured at Texas event
9. Chemist monitors nanotechnologys environmental impact
10. UC-developed technology to assist research and genetic drug delivery
11. NYU School of Medicine presents biomedical researchers Dart/NYU Biotechnology Achievement Awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/11/2014)... , Dec. 10, 2014  That blood pressure plays a ... while. Hypertension – the medical term for high blood pressure ... 1800s, and the inflatable cuff that,s used in measuring blood ... mean there,s nothing new about hypertension, its triggers and its ... about the condition and the best ways to treat it. ...
(Date:12/10/2014)... WINSTON-SALEM, N.C. , Dec. 9, 2014  Wake Forest ... medical education building for its School of Medicine. Funding ... a larger capital campaign that will be publicly launched ... will be located in the former 60 series R.J. ... Forest Innovation Quarter. Construction will begin immediately with plans ...
(Date:12/5/2014)... Dec. 4, 2014 Increased emphasis on ... in new testing and inspection technologies. The convergence ... to a range of innovative test solutions. This ... Generation Y, which is generally more inclined towards ... product development strategies of test equipment vendors will ...
Breaking Biology News(10 mins):Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4
... in the rich tapestry of biochemical signals that cause ... dramatically killed brain cancer cells by blocking those signals ... The unlikely pairing of cholesterol-lowering lovastatin and cyclopamine killed ... By contrast, using either agent alone wiped out ...
... detection of base sequence in duplex nucleic acid has ... "Heteropolymeric Triplex-Based Genomic Assay® to Detect Pathogens or Single-Nucleotide ... issue of the international, peer-reviewed, open access, online journal, ... a wealth of data relating to the assay of ...
... Baylor College of Medicine have discovered a new way to ... to enter cancer cells. , The research appears in the ... , All living cells defend themselves by walling off ... cocoon around the cell's inner machinery and its DNA blueprints. ...
Cached Biology News:Statin plus cancer drug deliver combo punch to brain cancer cells 2Triplex assay used to assay duplex genomic DNA 2Buckyballs used as 'passkey' into cancer cells 2
(Date:12/19/2014)... BioPlus Specialty Pharmacy ... has an expanded team of Regional Pharmaceutical Care ... prescriber offices in their regions, with specific areas ... a variety of Regional Pharmaceutical Care Liaisons specializing ... hepatitis C help prescribers understand all the new ...
(Date:12/19/2014)... 2014 Reports from CDC ... suffer from one or more chronic health conditions - ... can address some of these diseases, but may not ... sufferers face. While implanted nerve stimulation devices today offer ... nerve, which can induce side effects. , To ...
(Date:12/19/2014)... 2014 With only 2 weeks left ... on Sartorius Biohit products . The product specials include ... Electronic Pipette Trade-in Program, and free pipette tips. , ... around the world. They are ideal for lab technicians ... ,     Full volume range of 0.1 uL ...
(Date:12/19/2014)... , Dec. 18, 2014 Relmada Therapeutics, ... for the treatment of chronic pain, announced the results ... "This was a transformational year in Relmada,s ... future for our company," said Sergio Traversa , ... we have executed on key financial, human resource and ...
Breaking Biology Technology:BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 2BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 3Draper Wins GSK Funding for Smaller, Smarter Implantable Devices 2Major Pipette Distributor Pipette.com Announces Sartorius Year End Specials 2Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2
... II Study Shows 71% Objective Tumor Response Rate in Evaluable ... Secondary Endpoint Evaluation Shows Promising 7.4 Month Median Progression Free ... Fla. and TUSTIN, Calif., June 1 Peregrine Pharmaceuticals, Inc. ... from a Phase II trial of its lead anti-phosphatidylserine antibody ...
... CHICAGO, June 1 UCB, Inc. and the ... of the 2009 Research Awards in Inflammatory Bowel Disease (IBD) ... research grant for their original clinical or basic research, totaling ... the CDWG Steering Committee and the awards were funded by ...
... today that promising results from ongoing clinical studies in prostate, ... AT-101, an oral, pan-Bcl-2 inhibitor, at the 2009 American Society ... Orlando, Florida. , , (Logo: ... , "We are delighted with the depth and breadth ...
Cached Biology Technology:Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 2Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 3Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 4Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 5Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 6UCB and Crohn's Disease Working Group Award $175,000 in Research Grants to Gastroenterology Fellows 2Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT-101 in Prostate, Brain, and Lung Cancers at 2009 ASCO Annual Meeting 2Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT-101 in Prostate, Brain, and Lung Cancers at 2009 ASCO Annual Meeting 3Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT-101 in Prostate, Brain, and Lung Cancers at 2009 ASCO Annual Meeting 4Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT-101 in Prostate, Brain, and Lung Cancers at 2009 ASCO Annual Meeting 5
... Recognizes K+ Cl- Cotransporter-1 ... no significant sequence homology ... CCC.,SPECIES REACTIVITIES: The immunogen ... in human, mouse, porcine ...
...
Anti-G-alpha-i 1 G-Protein Host: mouse monoclonal Species Reactivity: human, mouse, rat Applications: WB Storage: 4C...
oligophrenin-1 (H-100)...
Biology Products: